会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • 2-Amino-4,5-Trisubstituted Thiazolyl Derivatives
    • 2-氨基-4,5-三取代噻唑衍生物
    • US20070203189A1
    • 2007-08-30
    • US11742741
    • 2007-05-01
    • Christopher LoveGuy Van LommenJulien Georges DoyonJean-Pierre BongartzMarcel Van der AaRobert HendrickxPeter Jacobus Antonius BuijnstersLudwig CooymansNele VandermaesenErwin CoesemansGustaaf Boeckx
    • Christopher LoveGuy Van LommenJulien Georges DoyonJean-Pierre BongartzMarcel Van der AaRobert HendrickxPeter Jacobus Antonius BuijnstersLudwig CooymansNele VandermaesenErwin CoesemansGustaaf Boeckx
    • A61K31/454A61K31/427A61K31/426C07D417/02
    • C07D417/04C07D277/42C07D471/04
    • This invention concerns the use of a compound of formula (I′) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is halo; C1-6alkyl; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; aminocarbonyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, amino substituted with piperidinyl, amino substituted with C1-4alkyl substituted piperidinyl, mono- or di(C1-6alkyl)amino, aminocarbonyl, mono- or di(C1-6alkyl)aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkyloxy, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; polyhaloC1-4alkyl; cyano; amino; mono- or di(C1-6alkyl)aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; aminoS(═O)2—; mono- or di(C1-6alkyl)aminoS(═O)2; —C(═N—Rx)NRyRz; Q is optionally substituted C3-6cycloalkyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzthiazolyl, benzoxazolyl, benzimidazolyl, indazolyl, or imidazopyridyl, or Q is a radical of formula L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through TNF-α and/or IL-12.
    • 本发明涉及式(I')化合物的N-氧化物,药学上可接受的加成盐,季胺及其立体化学异构体形式的用途,其中Z为卤素; C 1-6烷基; C 1-6烷基羰基; C 1-6烷氧基羰基; 氨基羰基; 用羟基,羧基,氰基,氨基,被哌啶取代的氨基,被C 1-4烷基取代的哌啶基取代的氨基,单或二( C 1-6烷基)氨基,氨基羰基,一或二(C 1-6烷基)氨基羰基,C 1-6烷氧基羰基, C 1-6烷基氧基,哌啶基,哌嗪基,吗啉基,硫代吗啉基; 多卤代1-4烷基; 氰基; 氨基; 单或二(C 1-6烷基)氨基羰基; C 1-6烷氧基羰基; C 1-6烷基羰基氧基; 氨基-S(-O)2 - ; 单或二(C 1-6烷基)氨基S(-O)2; -C(-N-R x X)NR z R z Z; Q是任选取代的C 3-6环烷基,苯基,吡啶基,嘧啶基,吡嗪基,哒嗪基,苯并噻唑基,苯并恶唑基,苯并咪唑基,吲唑基或咪唑并吡啶基,或Q是式L的基团是任选取代的苯基 或任选取代的单环5或6元部分饱和或芳族杂环或双环部分饱和或芳族杂环; 芳基是任选取代的苯基; 用于制备用于预防或治疗通过TNF-α和/或IL-12介导的炎症和/或自身免疫疾病的药物。
    • 6. 发明申请
    • Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
    • US20060183747A1
    • 2006-08-17
    • US10565065
    • 2004-07-12
    • Eddy FreyneChristopher LoveLudwig CooymansNele VandermaesenPeter Jacobus BuijnstersMarc WillemsWerner Embrechts
    • Eddy FreyneChristopher LoveLudwig CooymansNele VandermaesenPeter Jacobus BuijnstersMarc WillemsWerner Embrechts
    • A61K31/519C07D487/02
    • C07D487/04
    • This invention concerns compounds of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; or optionally substituted C1-6alkyloxyC1-6alkylcarbonyl; X1 represents a direct bond; —(CH2)n3— or —(CH2)n4—X1a—X1b—; R2 represents optionally substituted C3-7cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one hetetoatom selected from O, S or N; benzoxazolyl or a radical of formula X2 represents a direct bond; —NR1—; —NR1—(CH2)n3—; —O—; —O—(CH2)n3—; —C(═O)—; —C(═O)—(CH2)n3—; —C(═O)—NR5—(CH2)n3—; —C(═S)—; —S—; —S(═O)n1—; —(CH2)n3—; —(CH2)n4—X1a—X1b—; —X1a—X1b—(CH2)n4—; —S(═O)n1—NR5—(CH2)n3—NR5— or —S(═O)n1—NR5—(CH2)n3—; R3 represents an optionally substituted 5- or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, or a 9- or 10-membered bicyclic heterocycle containing at least one heteroatom selected from O, S or N; R4 represents hydrogen; halo; hydroxy; optionally substituted C1-4alkyl; optionally substituted C2-4alkenyl or C2-4alkynyl; polyhaloC1-3alkyl; optionally substituted C1-4alkyloxy; polyhaloC1-3alkyloxy; C1-4alkylthio; polyhaloC1-3alkylthio; C1-4alkyloxycarbonyl; C1-4alkylcarbonyloxy; C1-4alkylcarbonyl; polyhaloC1-4alkylcarbonyl; nitro; cyano; carboxyl; NR9R10; C(═O)NR9R10; —NR5—C(═O)—NR9R10; —NR5—C(═O)—R11; —S(═O)n1—R11; —NR5—S(═O)n1—R11; —S—CN; —NR5—CN; their use, pharmaceutical compositions comprising them and processes for their preparation.
    • 7. 发明申请
    • Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
    • US20060205721A1
    • 2006-09-14
    • US10564844
    • 2004-07-12
    • Eddy Edgard FreyneChristopher LoveLudwig CooymansNele VandermaesenPeter Jacobus Buijinsters
    • Eddy Edgard FreyneChristopher LoveLudwig CooymansNele VandermaesenPeter Jacobus Buijinsters
    • A61K31/5377A61K31/519C07D487/02
    • C07D487/04
    • This invention concerns a compound of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 represents hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; or C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl; X represents a direct bond; —(CH2)n3— or —(CH2)n4—X1a—X1b—; R2 represents C3-7cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula wherein said R2 substituent may optionally be substituted; R3 represents halo; hydroxy; optionally substituted C1-6alkyl; C2-6alkenyl or C2-6alkynyl, each optionally substituted; optionally substituted polyhaloC1-6alkyl; optionally substituted C1-6alkyloxy; optionally substituted polyhaloC1-6alkyloxy; C1-6alkylthio; polyhaloC1-6alkylthio; C1-6alkyl-oxycarbonyl; C1-6alkylcarbonyloxy; C1-6alkylcarbonyl; polyhaloC1-6alkylcarbonyl; cyano; carboxyl; aryloxy; arylthio; arylcarbonyl; NR6bR7b; C(═O)—NR6bR7b; —NR5—C(═O)—NR6bR7b; —NR5—C(═O)—R5; —S(═O)n1—R8b; —NR5—S(═O)n1—R8b; —S—CN; —NR5—CN; R4 represents hydrogen; halo; hydroxy; optionally substituted C1-4alkyl; C2-4alkenyl or C2-4alkynyl, each optionally substituted; polyhaloC1-3alkyl; optionally substituted C1-4alkyloxy; polyhaloC1-3alkyloxy; C1-4alkylthio; polyhaloC1-3alkylthio; C1-4alkyloxycarbonyl; C1-4alkylcarbonyloxy; C1-4alkylcarbonyl; polyhaloC1-4alkylcarbonyl; nitro; cyano; carboxyl; NR10R11; C(═O)NR10R11; —NR5—C(═O)—NR10R11; —NR5—C(═O)—R5; —S(═O)Sn1—R12; —NR5—S(═O)n1—R12; —S—CN; —NR5—CN; their use, pharmaceutical compositions comprising them and processes for their preparation.